[go: up one dir, main page]

MX2018009461A - Conjugados de anticuerpo-medicamento que se enfocan a la uparap. - Google Patents

Conjugados de anticuerpo-medicamento que se enfocan a la uparap.

Info

Publication number
MX2018009461A
MX2018009461A MX2018009461A MX2018009461A MX2018009461A MX 2018009461 A MX2018009461 A MX 2018009461A MX 2018009461 A MX2018009461 A MX 2018009461A MX 2018009461 A MX2018009461 A MX 2018009461A MX 2018009461 A MX2018009461 A MX 2018009461A
Authority
MX
Mexico
Prior art keywords
uparap
antibody
focusing
conjugates
medicinal
Prior art date
Application number
MX2018009461A
Other languages
English (en)
Inventor
Nielsen Christoffer
Behrendt Niels
Henning Engelholm Lars
Original Assignee
Rigshospitalet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigshospitalet filed Critical Rigshospitalet
Publication of MX2018009461A publication Critical patent/MX2018009461A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con conjugados que se enfocan a la uPARAP, en particular conjugados de anticuerpo-medicamento (ADCs) particulares que comprenden anticuerpos monoclonales dirigidos contra la región N-terminal de la uPARAP, y su uso en el suministro de agentes activos a células y tejidos que expresan la uPARAP. La invención se relaciona además con el uso de los ADC en el tratamiento de enfermedades que implican células que expresan la uPARAP, tales como el cáncer.
MX2018009461A 2016-02-05 2017-02-03 Conjugados de anticuerpo-medicamento que se enfocan a la uparap. MX2018009461A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201670063 2016-02-05
DKPA201670834 2016-10-24
PCT/DK2017/050024 WO2017133745A1 (en) 2016-02-05 2017-02-03 ANTIBODY-DRUG CONJUGATES TARGETING uPARAP

Publications (1)

Publication Number Publication Date
MX2018009461A true MX2018009461A (es) 2018-12-11

Family

ID=58108381

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009461A MX2018009461A (es) 2016-02-05 2017-02-03 Conjugados de anticuerpo-medicamento que se enfocan a la uparap.
MX2022014231A MX2022014231A (es) 2016-02-05 2018-08-02 Conjugados de anticuerpo-farmaco que se enfocan a la uparap.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022014231A MX2022014231A (es) 2016-02-05 2018-08-02 Conjugados de anticuerpo-farmaco que se enfocan a la uparap.

Country Status (23)

Country Link
US (3) US10940213B2 (es)
EP (2) EP3895736B1 (es)
JP (2) JP7125059B2 (es)
KR (1) KR102904012B1 (es)
CN (1) CN108883197B (es)
AU (1) AU2017215869B2 (es)
BR (1) BR112018015448A2 (es)
CA (1) CA3013677C (es)
CY (2) CY1124280T1 (es)
DK (2) DK3411076T3 (es)
ES (2) ES2874668T3 (es)
FI (1) FI3895736T3 (es)
HR (2) HRP20211152T1 (es)
HU (2) HUE061880T2 (es)
LT (2) LT3411076T (es)
MX (2) MX2018009461A (es)
PL (2) PL3895736T3 (es)
PT (2) PT3411076T (es)
RS (2) RS62115B1 (es)
RU (1) RU2740311C2 (es)
SI (2) SI3411076T1 (es)
SM (1) SMT202100386T1 (es)
WO (1) WO2017133745A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3895736B1 (en) 2016-02-05 2023-04-19 Rigshospitalet Antibody-drug conjugates targeting uparap
EP4363447A1 (en) * 2021-06-29 2024-05-08 Rigshospitalet Antibody-drug conjugates comprising humanized antibodies targeting urokinase type plasminogen activator receptor associated protein (uparap)
JP2026502232A (ja) 2022-12-28 2026-01-21 アセンド エーピーエス エキサテカン誘導体を含むｕＰＡＲＡＰを標的とする抗体薬物複合体
WO2025099152A1 (en) * 2023-11-08 2025-05-15 Rigshospitalet Antibodies and molecular conjugates thereof targeting upar
WO2025141153A1 (en) 2023-12-29 2025-07-03 Oncomatryx Biopharma, S.L. Endo180 targeted antibody-drug conjugates
EP4578463A1 (en) * 2023-12-29 2025-07-02 Oncomatryx Biopharma, S.L. Endo-180 targeted antibody-drug conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
SI2357006T1 (sl) 2002-07-31 2016-01-29 Seattle Genetics, Inc. Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni
JP2004137151A (ja) 2002-10-15 2004-05-13 Keio Gijuku 脳腫瘍の治療・診断薬
CN104861066B (zh) 2009-03-23 2018-05-08 夸克制药公司 治疗癌症和纤维化疾病的化合物组合物和方法
CN104080480A (zh) * 2012-01-01 2014-10-01 奇比艾企业有限公司 用于选择性递送治疗剂和诊断剂的endo180靶向微粒
RU2530553C2 (ru) * 2012-11-07 2014-10-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Рекомбинантное однодоменное антитело, способное специфически связывать фактор некроза опухолей человека, и его производные
EP3895736B1 (en) 2016-02-05 2023-04-19 Rigshospitalet Antibody-drug conjugates targeting uparap

Also Published As

Publication number Publication date
US10940213B2 (en) 2021-03-09
CN108883197B (zh) 2022-05-10
SI3411076T1 (sl) 2021-09-30
US20240226317A9 (en) 2024-07-11
CY1124280T1 (el) 2022-07-22
RU2018125309A (ru) 2020-03-06
EP3411076B1 (en) 2021-04-28
EP3895736B1 (en) 2023-04-19
HUE054938T2 (hu) 2021-10-28
LT3895736T (lt) 2023-06-12
FI3895736T3 (fi) 2023-06-26
BR112018015448A2 (en) 2018-12-18
CN108883197A (zh) 2018-11-23
SI3895736T1 (sl) 2023-07-31
RU2018125309A3 (es) 2020-04-27
CY1126032T1 (el) 2023-11-15
HK1258338A1 (en) 2019-11-08
AU2017215869A1 (en) 2018-07-19
DK3411076T3 (da) 2021-07-26
PL3411076T3 (pl) 2021-11-02
KR102904012B1 (ko) 2025-12-26
JP7125059B2 (ja) 2022-08-24
US20210162062A1 (en) 2021-06-03
KR20180105155A (ko) 2018-09-27
JP2022064906A (ja) 2022-04-26
ES2946073T3 (es) 2023-07-12
RS62115B1 (sr) 2021-08-31
US11819552B2 (en) 2023-11-21
EP3411076A1 (en) 2018-12-12
WO2017133745A1 (en) 2017-08-10
ES2874668T3 (es) 2021-11-05
JP7304595B2 (ja) 2023-07-07
CA3013677A1 (en) 2017-08-10
PT3411076T (pt) 2021-06-17
US20240131179A1 (en) 2024-04-25
HRP20211152T1 (hr) 2021-10-15
DK3895736T3 (da) 2023-07-24
EP3895736A1 (en) 2021-10-20
LT3411076T (lt) 2021-07-26
JP2019511205A (ja) 2019-04-25
PT3895736T (pt) 2023-06-02
PL3895736T3 (pl) 2023-07-24
CA3013677C (en) 2025-09-23
HRP20230505T1 (hr) 2023-08-04
AU2017215869B2 (en) 2024-02-01
HUE061880T2 (hu) 2023-08-28
US20190046658A1 (en) 2019-02-14
DK3895736T5 (da) 2024-06-10
RS64219B1 (sr) 2023-06-30
MX2022014231A (es) 2022-12-07
RU2740311C2 (ru) 2021-01-13
SMT202100386T1 (it) 2021-09-14

Similar Documents

Publication Publication Date Title
MX2018009461A (es) Conjugados de anticuerpo-medicamento que se enfocan a la uparap.
CO2020006865A2 (es) Composiciones y métodos para el agotamiento de células cd5+
MX2022014125A (es) Anticuerpos y conjugados de los mismos.
CL2018001971A1 (es) Ror1 composiciones de anticuerpos y métodos relacionados
CL2017001920A1 (es) Anticuerpos humanos contra glicoproteína del virus ébola
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
MX2019005879A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
AR120147A1 (es) Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco
MX2020007077A (es) Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
MX2016011619A (es) Anticuerpos anti-egfrviii y usos de los mismos.
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
CL2019001745A1 (es) Conjugados anticuerpo droga para ablacion de celulas madre hematopoyeticas.
CL2016001760A1 (es) Adc de duocarmicina que demuestran mayor actividad antitumoral in vivo.
CL2016001743A1 (es) Conjugados de anticuerpo-fármaco (adc) de duocarmicina para su uso en el tratamiento de cáncer de endometrio.
MX379396B (es) Conjugados de pirrolobenzodiazepina y anticuerpo.
EA201692002A1 (ru) Стабильные составы для антител к cd19 и конъюгатов антитело-лекарственное средство
CL2018001334A1 (es) Anticuerpos y conjugados anticuerpo-fármaco anti-5t4.
CL2024003094A1 (es) Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados.
PE20200746A1 (es) AGENTES DE iARN PARA LA INHIBICION DE LA EXPRESION DE ALFA-ENAC Y METODOS DE USO
CO2018000414A2 (es) Inmunoconjugados de il22
MX2023015471A (es) Conjugados de anticuerpo-farmaco que comprenden anticuerpos humanizados que eligen como blanco la proteina asociada al receptor activador de plasminogeno tipo uroquinasa (uparap).
BR112021008012A2 (pt) Conjugados de anticorpo de cisteína engenheirada-fármaco com ligantes contendo peptídeo